Search filters
Filters
Clear All

Phase

  • 12
  • 39
  • 2
  • 26
  • 1
  • 16
  • 1
  • 251
  • 352
  • 262
  • 4
  • 25
  • 323

Found 352 oncology trials

A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 03023: A Phase 1, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis

99 years or below
All genders
Please see the Protocol, Section 2 (Objectives and Endpoints) Please see the Protocol, Section 2 (Objectives and Endpoints) Please see the Protocol, Section 2 (Objectives and Endpoints)
Learn More

UPCC 25423 A Phase 1, Open-label, Dose-finding Study of CC-91633 (BMS-986397) in Subjects with Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

99 years or below
All genders
Study CC-91633-AML-001 is a Phase 1, open-label, dose escalation and expansion, first-in-human (FIH) clinical study of CC-91633 (BMS-986397) in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). We would like to rely on WCG IRB as …
Learn More

EAY191 Molecular Analysis for Combination Therapy Choice (ComboMATCH)

99 years or below
All genders
The ComboMATCH precision medicine trial will include multiple components: this non-treatment ComboMATCH Registration Trial, an informatics component for specimen and genomic data management, and multiple ComboMATCH Treatment Trials.
Learn More

UPCC 23423: Full Protocol Title A Phase 1b/2 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib (LANRA) in Combination with the FLT3 Inhibitor Gilteritinib, in Patients with FLT

99 years or below
All genders
This study tests an investigational drug called LANRA as a possible treatment for people with relapsed or refractory FLT3-mutated AML. This study will take place in 2 parts. In Part 1 (dose escalation), the main purpose is to determine the maximal dose of LANRA that can be safely administered and …
Learn More

UPCC 26423 Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD33 Linked to TCR and 4-1BB Signaling Domains in Combination with CD33KO-HSPC in Subjects with Refractory or Relapsed Acute Myeloid Leukemia

99 years or below
All genders
Please refer to Protocol Section 3.2 (Study Objectives and Endpoints). Please refer to Protocol Section 3.2 (Study Objectives and Endpoints). Please refer to Protocol Section 3.2 (Study Objectives and Endpoints).
Learn More

UPCC 12223: A Phase 2, Open-label, Multicenter Study Investigating RP3 Oncolytic Immunotherapy in Combination with First- or Second-line Therapy in Patients with Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma

99 years or below
All genders
Please refer to Protocol section 3 (Objectives and Endpoints). Please refer to Protocol section 3 (Objectives and Endpoints). Please refer to Protocol section 3 (Objectives and Endpoints).
Learn More

UPCC 09223: A Phase 2 Clinical Trial Investigating Oncolytic Immunotherapy in Combination with Atezolizumab and bevacizumab for the Treatment of Patients with Advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma

99 years or below
All genders
Please refer to Section 3.1 of the full protocol (Objectives and Endpoints) Please refer to Section 3.1 of the full protocol (Objectives and Endpoints) Please refer to Section 3.1 of the full protocol (Objectives and Endpoints)
Learn More

UPCC 24423: A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

99 years or below
All genders
Please refer to Protocol Section 3.0 (Objectives and Endpoints). Please refer to Protocol Section 3.0 (Objectives and Endpoints). Please refer to Protocol Section 3.0 (Objectives and Endpoints).
Learn More

UPCC 43422: Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

99 years or below
All genders
Please refer to Protocol 17-054, Section 2.0 (Objectives and Scientific Aims) Please refer to Protocol 17-054, Section 14.0 (Biostatistics, Primary Endpoints) Please refer to Protocol 17-054, Section 14.0 (Biostatistics, Secondary Endpoints)
Learn More

UPCC 49422: Phase IB/II of CPX-351 as maintenance therapy in AML patients ineligible for bone marrow transplantation

99 years or below
All genders
Please refer to Protocol, Section 2.0 (Objectives) Please refer to Protocol, Section 4.0 (Study Endpoints) Please refer to Protocol, Section 4.0 (Study Endpoints)
Learn More
281 - 290 of 352